Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?
F1000Research · 2025
DOI: 10.12688/f1000research.156983.2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift F1000Research, 2025. Verfasst von Christos Ntais und 3 weiteren Autor:innen. Beteiligte Einrichtung: Healthcare Management Program, School of Economics & Management, Open University of Cyprus, Nicosia, Cyprus. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Arthritis, Rheumatoid, Antirheumatic Agents, Delivery of Health Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune-mediated inflammatory diseases like rheumatoid arthritis (RA) have been successfully treated using biologic disease-modifying antirheumatic drugs. These medications are not utilized as first-line treatment, in part because of their high cost, but they are frequently seen to be cost-effective for RA patient populations that do not respond adequately to conventional disease-modifying antirheumatic drugs. Moreover, not all RA patients who meet clinical eligibility criteria can access biologics, not even as second-line therapy. Recently, there has been an increasing interest in biosimilars that are highly comparable to their originator biologics in terms of efficacy and safety but generally come at a lower price. This review summarizes the potential role of biosimilars in reducing RA expenditure and increasing RA patient access to biologic therapies. As the global landscape for biosimilars continues to evolve, it is essential to consider the unique challenges and opportunities in different healthcare systems. By leveraging the potential of biosimilars, healthcare systems can improve RA management, ease its economic burden and ensure that patients have access to effective and affordable treatments. The future of RA treatment lies in the integration of biosimilars into clinical practice, offering hope for more sustainable and equitable healthcare systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Healthcare Management Program, School of Economics & Management, Open University of Cyprus, Nicosia, Cyprus.
- Healthcare Management Program, School of Social Sciences, Hellenic Open University, Patras, Greece.
- Department of Economics and Sustainable Development, Harokopio University, Athens, Greece.
- Department of Management Science and Technology, Hellenic Mediterranean University, Agios Nikolaos, Crete, Greece.
ORCID-Profile: Christos Ntais, John Fanourgiakis, Michael A Talias
Zitieren
APA
Ntais, C., Kontodimopoulos, N., Fanourgiakis, J., & Talias, M. A. (2025). Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?. F1000Research. https://doi.org/10.12688/f1000research.156983.2
Vancouver
Ntais C, Kontodimopoulos N, Fanourgiakis J, Talias MA. Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?. F1000Research. 2025. doi:10.12688/f1000research.156983.2
BibTeX
@article{Ntais2025,
author = {Ntais, Christos and Kontodimopoulos, Nikolaos and Fanourgiakis, John and Talias, Michael A},
title = {Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?},
journal = {F1000Research},
year = {2025},
doi = {10.12688/f1000research.156983.2}
}
EUVIMED